Trials / Completed
CompletedNCT00560235
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-751,871 | Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-03-01
- Completion
- 2012-10-01
- First posted
- 2007-11-19
- Last updated
- 2015-10-28
- Results posted
- 2014-02-28
Locations
37 sites across 11 countries: United States, Australia, Brazil, Canada, Chile, France, Germany, Israel, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00560235. Inclusion in this directory is not an endorsement.